Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24037547 | 0.74 | KDM4E (0.30) | KDM4E | |
| SCHEMBL10743642 | 0.71 | RAB9A (0.41) | KDM4EMEN1KMT2AMAPT | |
| SCHEMBL20798955 | 0.70 | IDO1 (0.31) | — | |
| SCHEMBL24983453 | 0.69 | — | — | |
| SCHEMBL13112244 | 0.68 | KDM4E (0.40) | KDM4EMAPT | |
| SCHEMBL30577551 | 0.67 | ADORA3 (0.36) | KMT2A | |
| SCHEMBL23176064 | 0.65 | NPC1 (0.36) | KDM4EMAPT | |
| SCHEMBL3396471 | 0.64 | — | — | |
| SCHEMBL15830161 | 0.62 | — | — | |
| SCHEMBL24197690 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021259208-A1 | TYK-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-12-30 | — | — | WO | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | FREDERIKSEN MATHIAS | 2010-06-10 | — | — | US | disclosed |
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | FREDERIKSEN MATHIAS | 2010-06-10 | — | — | US | disclosed |
| WO-2008062044-A1 | 2-HYDROXY-1,3-DIAMINOPROPANE DERIVATIVES | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | KDM4E 3060/4885MEN1 380/4885KMT2A 1005/4885 |
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | KDM4E 3716/4885MEN1 276/4885KMT2A 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.